Exiqon Secures Funding to Accelerate Growth
News Nov 12, 2015
The Note is fully subscribed, subject to customary conditions, by Ture Invest AB, a Stockholm based direct lender and alternative credit investor, and will be sought to be admitted to trading on the First North Bond Market of NASDAQ Copenhagen A/S.
Proceeds from the Note will be used to further develop the company’s recently launched cloud platform for life science researchers: XploreRNA™, and to accelerate growth by expanding the company’s product offering within RNA analysis, in addition to general corporate purposes, including refinancing of current debt.
“This new financing will allow us to more rapidly capture the business potential of our XploreRNA™ cloud platform which holds the potential of becoming a leading e-commerce platform for researchers in our market. We now have funding to complete the company’s transition towards becoming the leading provider of customized solutions for RNA analysis by expanding our product offering for RNA analysis, including RNA sequencing,” said President and CEO, Dr. Lars Kongsbak.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.